Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Apolipoprotein B in type 1 diabetes

Nature Reviews Endocrinology volume 5, page 587 (2009)Cite this article

Access through your institution
Buy or subscribe

Mazanderani, A. B. et al. Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy. Clin. Biochem. 42, 1218–1221 (2009).

Reduction of cardiovascular complications as a result of dyslipidemia in patients with diabetes mellitus is achieved through tight glycemic control and the use of lipid-lowering therapies. A new study of cardiovascular disease (CVD) risk and response to lipid-lowering therapy suggests that apolipoprotein B is a more appropriate indicator than LDL cholesterol.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Linda Koch
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koch, L. Apolipoprotein B in type 1 diabetes. Nat Rev Endocrinol 5, 587 (2009). https://doi.org/10.1038/nrendo.2009.169

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2009.169

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing